{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:32:58Z","timestamp":1790695978897,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.ygyno.2012.02.019","type":"journal-article","created":{"date-parts":[[2012,2,21]],"date-time":"2012-02-21T13:46:26Z","timestamp":1329831986000},"page":"367-371","source":"Crossref","is-referenced-by-count":97,"title":["A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study"],"prefix":"10.1016","volume":"125","author":[{"given":"Don S.","family":"Dizon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Blessing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Penson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan L.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn M.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"DiSilvestro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda Nickles","family":"Fader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2012.02.019_bb0005","unstructured":"American Cancer Society Cancer Facts & Figures 2010. (2010)."},{"key":"10.1016\/j.ygyno.2012.02.019_bb0010","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2012.02.019_bb0015","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.02.019_bb0020","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.02.019_bb0025","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ygyno.2006.03.018","article-title":"Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group","volume":"103","author":"Brewer","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.02.019_bb0030","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1517\/13543784.16.5.659","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"16","author":"Rasheed","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ygyno.2012.02.019_bb0035","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1158\/1535-7163.MCT-06-0111","article-title":"Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies","volume":"5","author":"Qian","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ygyno.2012.02.019_bb0040","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.ejca.2010.02.047","article-title":"Phase II trial of the histone deacetylase inhibitor Belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumors","volume":"46","author":"Mackay","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2012.02.019_bb0045","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2010.32.4467","article-title":"Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors","volume":"29","author":"Giaccone","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.02.019_bb0050","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/JTO.0b013e318191520c","article-title":"Phase II study of Belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma","volume":"4","author":"Ramalingam","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ygyno.2012.02.019_bb0055","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.bjc.6605726","article-title":"A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and\/or paclitaxel in patients with solid tumours","volume":"103","author":"Lassen","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2012.02.019_bb0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/jco.2008.26.15_suppl.5519","article-title":"Phase II multicenter trial of the histone deactylase inhibitor (HDACi) belinostat, carboplatin and paclitaxel (BelCaP) in patients (pts) with relapsed epithelial ovarian cancer (EOC)","volume":"26","author":"Finkler","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.02.019_bb0065","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2012.02.019_bb0070","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jnci\/djh081","article-title":"Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)","volume":"96","author":"Rustin","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2012.02.019_bb0075","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/(SICI)1097-0258(19981030)17:20<2301::AID-SIM927>3.0.CO;2-X","article-title":"Optimal flexible designs in phase II clinical trials","volume":"17","author":"Chen","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.ygyno.2012.02.019_bb0080","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.ejca.2009.01.003","article-title":"The promises and pitfalls of epigenetic therapies in solid tumours","volume":"45","author":"Graham","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2012.02.019_bb0085","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1593\/neo.08474","article-title":"Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas","volume":"10","author":"Weichert","year":"2008","journal-title":"Neoplasia"},{"key":"10.1016\/j.ygyno.2012.02.019_bb0090","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.02.019_bb0095","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1200\/JCO.2009.23.1811","article-title":"Phase II trials in Journal of Clinical Oncology","volume":"27","author":"Cannistra","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.02.019_bb0100","volume":"29","author":"Yardley","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581200145X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581200145X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,25]],"date-time":"2018-11-25T19:20:07Z","timestamp":1543173607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581200145X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S009082581200145X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2012.02.019","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}